Las Vegas—In the United States, clinical trials of treatments for inflammatory bowel disease enroll a smaller proportion of Black and Hispanic patients than white or Asian patients, at rates that do not track with the prevalence of diseases in these groups, according to research presented at the 2021 annual meeting of the American College of Gastroenterology.
The finding could mean that any new treatments that emerge from such clinical trials are not generalizable to all population groups